Glioblastoma -Opportunity Analysis and Forecasts to 2024

1
Glioblastoma?-Opportunity Analysis and Forecasts
to 2024
2
Opportunity Analyzer Glioblastoma - Opportunity
Analysis and Forecasts to 2024
Glioblastoma multiform (GBM) is characterized as
a disease with some of the highest unmet needs in
oncology, with patients having a median overall
survival (OS) of between one and two years. The
lack of therapies is primarily due to the
inability of drugs to penetrate the blood-brain
barrier (BBB). The GBM market is currently
dominated by temozolomide and Avast in which are
considered as standards of care in newly
diagnosed and recurrent settings, respectively.
Between 2014 and 2024, the market is set to
undergo substantial growth due to a number
companies developing therapies in the late-stage
pipeline, which is dominated by immunotherapies.
On one hand, the main drivers of growth will be
the launch of EGFR-targeting therapies such as
Rintega and ABT-414, as well as the checkpoint
inhibitor Opdivo. Furthermore, the launch of
autologous cell vaccines such as ICT-107 and
DCVax-L will also impact the GBM market. On the
other hand, the GBM market constrainers remain
modest with the increasing cost-consciousness of
healthcare providers, and the launch of
biosimilar bevacizumab in the 7MM (US, France,
Germany, Italy, Spain, UK and Japan).
www.absolutereports.com
sales_at_absolutereports.com
 1 408 520 9750 
3
Topics Revealed in this Report

• The main driver of the enormous expansion of the
  GBM market will be the launch of Opdivo for newly
  diagnosed and recurrent GBM. GlobalData forecasts
  significant patient uptake for Opdivo which will
  supersede Avastin to become the SoC in the
  recurrent setting.
• Risk Factors and Comorbidities
• Epidemiological Forecast for Brain
  Cancer(2014-2024)
• Identification of New Treatment Options for
  Patients with rGBM Refractory to Avastin
• Physicians and Specialists Included in this Study

www.absolutereports.com
sales_at_absolutereports.com
 1 408 520 9750 
4
Major/Key players AnalysisThe Research Provides
Company Overview, Business Description, SWOT
Analysis, Major Products/Services, Head Office,
etc. of Following Companies

• Arbor Pharmaceuticals
• AbbVie
• Bristol-Myers Squibb Company
• Celldex Therapeutics
• Fujifilm
• GreenPeptide
• Immunocellular Therapeutics
• Ono Pharmaceuticals
• Peregrine Pharmaceuticals
• Pfizer

www.absolutereports.com
sales_at_absolutereports.com
 1 408 520 9750 
5
Scope of the Report

• Overview of GBM, including epidemiology,
  etiology, pathophysiology, symptoms, diagnosis,
  and treatment guidelines.
• Annualized GBM therapeutics market revenue,
  average cost of therapy and treatment usage
  pattern data from 2014 and forecast for ten years
  to 2024.
• Key topics covered include strategic competitor
  assessment, market characterization, unmet needs,
  clinical trial mapping and implications for the
  GBM therapeutics market.
• Pipeline analysis comprehensive data split
  across different phases, emerging novel trends
  under development, and detailed analysis of
  late-stage pipeline drugs.
• Analysis of the current and future market
  competition in the global GBM therapeutics
  market. Insightful review of the key industry
  drivers, restraints and challenges. Each trend is
  independently researched to provide qualitative
  analysis of its implications.

www.absolutereports.com
sales_at_absolutereports.com
 1 408 520 9750 
6
Why one should buy this report?

• Develop and design your in-licensing and
  out-licensing strategies through a review of
  pipeline products and technologies, and by
  identifying the companies with the most robust
  pipeline. Additionally a list of acquisition
  targets included in the pipeline product company
  list.
• Develop business strategies by understanding the
  trends shaping and driving the global GBM
  therapeutics market.
• Drive revenues by understanding the key trends,
  innovative products and technologies, market
  segments, and companies likely to impact the
  global GBM therapeutics market in future.
• Formulate effective sales and marketing
  strategies by understanding the competitive
  landscape and by analysing the performance of
  various competitors.
• Identify emerging players with potentially strong
  product portfolios and create effective
  counter-strategies to gain a competitive
  advantage.
• Track drug sales in the global GBM therapeutics
  market from 2014-2024.

www.absolutereports.com
sales_at_absolutereports.com
 1 408 520 9750 
7
Report Details

• No. Of Pages 206
• No of Tables 75
• No. Figures 23
• Price 9495 (Single User Licence)

www.absolutereports.com
sales_at_absolutereports.com
 1 408 520 9750 
8
Contact Mr. Ameya Pingaley
www.absolutereports.com
sales_at_absolutereports.com
 1 408 520 9750